ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions
View by Date

Sunday, November 10, 2019

9:00AM-11:00AM
Abstract Number: 564
ASDAS Is More Important Than BASDAI in Advanced Ankylosing Spondylitis
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features
9:00AM-11:00AM
Abstract Number: 198
Assessing Care Quality in Rheumatology Services
Epidemiology & Public Health Poster I: RA
9:00AM-11:00AM
Abstract Number: 428
Assessing Meaningful Changes in Disease Activity as Clinical Trial Efficacy Measures for Cutaneous Lupus Erythematosus
Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes
9:00AM-11:00AM
Abstract Number: 655
Assessing Perceptions, Barriers, and Preferences to Exercise in Patients with Systemic Lupus Erythematosus
SLE – Clinical Poster I: Epidemiology & Pathogenesis
9:00AM-11:00AM
Abstract Number: 630
Assessing the Humanistic and Economic Burden of Enthesitis Among Patients with Peripheral and Axial Spondyloarthritis: Results from a Multi-National Real World Survey Database
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features
9:00AM-11:00AM
Abstract Number: 333
Assessing the Relationship Between Gout and Return to Hemodialysis Among U.S. Renal Transplant Patients
Metabolic & Crystal Arthropathies Poster I: Clinical
9:00AM-11:00AM
Abstract Number: 295
Assessing the Vascularization of Salivary Glands in Patients with Sjögren’s Syndrome – An OMERACT Ultrasound Group Reliability Exercise
Imaging Of Rheumatic Diseases Poster I
9:00AM-11:00AM
Abstract Number: 496
Assessment of Anti-Cyclic Citrullinated Protein and Connective Tissue Disease Screening Questionnaire in Healthy Adults from the Oklahoma Immune Cohort
RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis
9:00AM-11:00AM
Abstract Number: 528
Assessment of Bone and Cartilage Turnover Markers Following Treatment with Repository Corticotropin Injection in Patients with Persistently Active Rheumatoid Arthritis
RA – Treatments Poster I: Novel Treatments
9:00AM-11:00AM
Abstract Number: 420
Assessment of Fatigue in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Qualitative Study to Explore What Patients Feel Should Be Measured in Clinical Trials
Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes
9:00AM-11:00AM
Abstract Number: 743
Association Between Acute-phase Reactants, interleukin-6(IL6), Tumor Necrosis Factor-a(TNFa) and Disease Activity in Takayasu’s Arteritis During Follow-up with Repeated Evaluation of Vascular Imaging Manifestations
Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: 670
Association Between Ambient Air Pollutant Exposures and Childhood-Onset Systemic Lupus Erythematosus: A 12-Year Population-Based Cohort Study in Taiwan
SLE – Clinical Poster I: Epidemiology & Pathogenesis
9:00AM-11:00AM
Abstract Number: 643
Association Between Neutrophil to Lymphocyte, Monocyte to Lymphocyte, and Platelet to Lymphocyte Ratios and Lupus Disease Activity and Lupus Nephritis
SLE – Clinical Poster I: Epidemiology & Pathogenesis
9:00AM-11:00AM
Abstract Number: 635
Association Between Radiographic Progression and Cardiovascular Risk in Spondyloarthritis: Data from CoSpaR REGISTRY
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features
9:00AM-11:00AM
Abstract Number: 686
Association Between the Soluble Terminal Complement Complex C5b-9 (sC5b-9) and Signs of Active Kidney Disease in a Swiss SLE Cohort
SLE – Clinical Poster I: Epidemiology & Pathogenesis
  • «Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology